Darren Kelly

Entrepeneur In Residence, Melbourne

Darren is currently CEO and Managing Director of OccuRx and has more than 20 years of management and research experience in the life sciences sector, particularly relating to drug development.

Darren is also a Professor and Director of Biomedical Research in the Department of Medicine at The University of Melbourne, St Vincent’s Hospital Melbourne.

Darren was a Founder, CEO and Director of Fibrotech Therapeutics, a company developing orally active anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure.  Fibrotech was sold to Shire Plc for USD 75 million upfront including milestone payments up to 560m USD in 2014.

Darren’s scientific expertise lies in progressing pre-clinical novel interventions and developing experimental models of cardiovascular disease.  He has published over 200 manuscripts in the field of translational research and novel interventions many of which have had a direct impact on human disease.  Darren was awarded the prestigious TJ Neale award in 2009 for outstanding contribution to nephrology.

Darren has a PhD from the University of Melbourne, and is also a member of the Australian Institute of Company Directors, Ausbiotech, BioMelbourne Network and a Fellow of the American Society of Nephrology.